Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H7NO.FH |
| Molecular Weight | 129.1322 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
F.OCC1=CN=CC=C1
InChI
InChIKey=NMZZYGAYPQWLGY-UHFFFAOYSA-N
InChI=1S/C6H7NO.FH/c8-5-6-2-1-3-7-4-6;/h1-4,8H,5H2;1H
| Molecular Formula | FH |
| Molecular Weight | 20.0063 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H7NO |
| Molecular Weight | 109.1259 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Nicotinyl alcohol is a direct-acting vasolidator, that may decrease the blood pressure and it is a cholesterol-lowering agent. Nicotinyl alcohol as a tartrate salt led to the efficiency improvements in patients with intermittent claudication. In addition, nicotinyl alcohol alone or associated with other drugs was studied in the treatment of radicular syndromes; and was shown, that the effect had not been due to mechanical compression.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Other AEs: Increased appetite, Skin rash... Other AEs: Increased appetite (15%) Sources: Skin rash (36%) Itching (37%) Flushing (68%) Nausea (50%) Abdominal pain (15%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Abdominal pain | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Increased appetite | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Skin rash | 36% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Itching | 37% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Nausea | 50% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Flushing | 68% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Picolinyl ester fragmentation mechanism studies with application to the identification of acylcarnitine acyl groups following transesterification. | 2006 Nov |
|
| Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. | 2008 Mar 15 |
|
| Equilibria of 3-pyridylmethanol with copper(II). A comparative electron spin resonance study by the decomposition of spectra in liquid and frozen solutions. | 2008 Oct 16 |
|
| The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. | 2010 Jan |
|
| Copper (II) complexes of the anti-inflammatory drug naproxen and 3-pyridylmethanol as auxiliary ligand. Characterization, superoxide dismutase and catecholase--mimetic activities. | 2010 Sep |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:33:37 GMT 2023
by
admin
on
Sat Dec 16 08:33:37 GMT 2023
|
| Record UNII |
67656KJH8M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID201021265
Created by
admin on Sat Dec 16 08:33:37 GMT 2023 , Edited by admin on Sat Dec 16 08:33:37 GMT 2023
|
PRIMARY | |||
|
100000091147
Created by
admin on Sat Dec 16 08:33:37 GMT 2023 , Edited by admin on Sat Dec 16 08:33:37 GMT 2023
|
PRIMARY | |||
|
20333624
Created by
admin on Sat Dec 16 08:33:37 GMT 2023 , Edited by admin on Sat Dec 16 08:33:37 GMT 2023
|
PRIMARY | |||
|
62756-44-9
Created by
admin on Sat Dec 16 08:33:37 GMT 2023 , Edited by admin on Sat Dec 16 08:33:37 GMT 2023
|
PRIMARY | |||
|
67656KJH8M
Created by
admin on Sat Dec 16 08:33:37 GMT 2023 , Edited by admin on Sat Dec 16 08:33:37 GMT 2023
|
PRIMARY | |||
|
SUB30059
Created by
admin on Sat Dec 16 08:33:37 GMT 2023 , Edited by admin on Sat Dec 16 08:33:37 GMT 2023
|
PRIMARY |